OSUR earnings analysis
What we found in OSUR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
OraSure's Q2 2026 revenue increased to $30.639 million from $28 million in Q1, exceeding the prior $28.0 million-$30.0 million Q2 outlook, while diluted EPS improved from a negative $0.32 to a negative $0.20. The filing does not provide updated quantitative guidance, segment results, margin data, balance-sheet data, or cash-flow data in the supplied extract. Ongoing losses, share repurchases, and the NowDiagnostics litigation remain important investor considerations, although management reported effective disclosure controls and no material risk-factor changes.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Rebounded Sequentially
- Revenue was $30.639 million, approximately 9% above the prior quarter's $28 million and above the prior Q2 outlook range of $28.0 million to $30.0 million.
- EPS Loss Narrowed
- Diluted EPS improved to a loss of $0.20 from a loss of $0.32 in Q1 2026, although the result was below the $0.18 loss consensus estimate.
- Continued Share Repurchases
- The company repurchased 646,798 shares during the quarter under its repurchase program, with $17,960,005 remaining available at June 30, 2026.
- Controls Remained Effective
- Management concluded that disclosure controls were effective as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
- Repurchase Authorization Remains
- The company has a $40.0 million share repurchase authorization effective March 21, 2025, providing continuing capital-allocation flexibility.
- Trade-Secret Litigation Advances
- The NowDiagnostics preliminary injunction remains in place, and trial is scheduled for January 17, 2027, preserving a potential avenue to protect the company's proprietary information.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent Operating Losses
- The company reported diluted EPS of negative $0.20, a loss that was $0.02 worse than the negative $0.18 consensus estimate, indicating continuing earnings pressure despite sequential improvement.
- Capital Allocation and Liquidity
- The company repurchased 646,798 shares during the quarter while retaining $17,960,005 of authorization, which could compete with liquidity needs while the company remains loss-making.
- Pending Trade-Secret Litigation
- The NowDiagnostics dispute remains unresolved; a preliminary injunction is still in place and trial is scheduled for January 17, 2027, creating ongoing legal expense and execution uncertainty.
- Risk Disclosures Unchanged
- The 10-Q states that there were no material changes to the risk factors in the December 31, 2025 Form 10-K filed March 9, 2026; therefore, the filing does not identify mitigation of the previously disclosed risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
What they said about what is next.
The 10-Q does not provide new quantitative revenue or EPS guidance. The prior Q2 revenue outlook was $28.0 million to $30.0 million; current-quarter revenue was $30.639 million.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2026
- OraSure Technologies reported its Q1 2026 results with total revenues of $27.9 million, reflecting a 7% decline year-over-year. The company suffered a wider diluted EPS loss of -$0.24 compared to -$0.21 in Q1 2025,…
- 10-K · March 9, 2026
- OraSure (OTI) describes a two-pronged strategy of diagnostics products and sample management solutions, pursuing new regulatory clearances and M&A to diversify product offerings (acquired BioMedomics in November 2025).…
- 10-Q · August 6, 2025
- OraSure reported Q2 2025 net revenue of $31.24M, down sharply from $54.34M in Q2 2024 but slightly above Q1 2025. Gross margin was 42.1% while the company reported an operating loss of $18.03M and GAAP net loss of…
- 10-Q · August 6, 2024
- OraSure reported Q2 2024 net revenue of $54.335 million and a small GAAP net loss of $0.615 million (diluted EPS $(0.01)). Revenue was essentially flat sequentially (+$0.203 million vs Q1 2024) but down materially…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OSUR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever